| R - Respiratory System | Inhaled antiinfectives are classified in ATC group J - Antiinfectives for systemic use.
|
| | R05 - Cough and Cold Preparations | This group comprises a large number of preparations, most of which are combined preparations.
Cold preparations containing therapeutic levels of antiinfectives should be classified in ATC group J - Antiinfectives for systemic use.
Cold preparations with therapeutic levels of analgesics/anti-inflammatory agents should be classified in the respective N02/M01 groups.
Cold preparations with both antiinfectives and analgesics should be classified in ATC group J - Antiinfectives for systemic use.
Cold preparations with minimal amounts of analgesics are classified in R05X - Other cold preparations.
See also R01 - Nasal preparations, R02 - Throat preparations, and
R03D - Other systemic drugs for obstructive airway diseases.
| Fixed DDDs are assigned for combinations. These DDDs are based on an average dose regimen of three times daily, and dosages in the upper area of the recommended dose ranges are chosen. The strengths of the various components are not taken into consideration. E.g. 6 UD (= 30 ml) is the fixed DDD for products where the recommended dose is 5-10 ml each time administered.
|
| | R05C - Expectorants, Excl. Combinations with Cough Suppressants | This group comprises preparations with expectorants and mucolytics.
Combined preparations are classified at separate 5th levels using the code number 10. These may also contain e.g. antihistamines. Combinations with adrenergics, e.g. ambroxol and clenbuterol, used in e.g. bronchial asthma are classified in R03C - Adrenergics for systemic use.
Preparations, which contain small amounts of herbal extracts, menthol etc., are regarded as plain preparations.
|
| | R05CB - Mucolytics | Mesna in i.v. formulations used for the prophylaxis of urothelial toxicity is classified in V03AF. Mesna used as a mucolytic agent (e.g. administered by a nebuliser) is classified here.
All combined products of mucolytics are classified in R05CB10.
Combinations with xanthines are classified in R03DA.
Combinations with antiinflammatory agents are classified in M01.
| For acetylcysteine, the DDD for inhalation solution is higher than for the oral formulation, due to differences in the dosages recommended.
|
| | R05CB01 - Acetylcysteine | | Dose | Route of administration | Note |
|---|
| | O | | | | Inhal.solution | |
|
|
|
